Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Avacopan in a compassionate use programme for severe anti-neutrophil cytoplasmic antibody-associated vasculitis in Sweden.

Scandinavian journal of rheumatology·2026
Same author

Anatomical and functional characteristics of symptomatic post-TB lung disease.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2025
Same author

Impact of a White Matter Reference Region on the Relationship between Florbetapir PET Measurements of Amyloid Plaque Deposition and Measurements of Cognitive Decline.

medRxiv : the preprint server for health sciences·2025
Same author

Donanemab: Appropriate use recommendations.

The journal of prevention of Alzheimer's disease·2025
Same author

Evaluation of susceptibility to pyrazinamide and streptomycin, isoniazid, rifampin and ethambutol of Mycobacterium caprae strains isolated from European bison (Bison bonasus caucasicus) in the Bieszczady Mountains (Southern Poland).

Polish journal of veterinary sciences·2024
Same author

Performance of a Short Version of the Everyday Cognition Scale (ECog-12) to Detect Cognitive Impairment.

The journal of prevention of Alzheimer's disease..·2024
Same journal

Rifamycin-based regimens for preventive treatment in low TB incidence countries.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same journal

The Kochi Declaration 2024 - A catalyst for global TB elimination through private sector engagement.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same journal

Preventing lung function decline and pleural thickening after pleural TB: a systematic review.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same journal

Aircraft contact investigations for TB on domestic and inbound flights to the United States.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same journal

Treatment outcome of extracorporeal membrane oxygenation in critically ill patients with pulmonary TB.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same journal

Factors associated with sputum culture positivity of <i>Mycobacterium tuberculosis</i>.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
See all related articles

Related Experiment Video

Updated: May 17, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

Lessons from a randomised clinical trial for multidrug-resistant tuberculosis.

N Padayatchi1, W R Mac Kenzie, Y Hirsch-Moverman

  • 1Centre for AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
|November 8, 2012
PubMed
Summary
This summary is machine-generated.

Conducting clinical trials for multidrug-resistant tuberculosis (MDR-TB) faces significant recruitment and retention hurdles. Ensuring accurate drug administration requires robust administrative controls in MDR-TB treatment research.

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Related Experiment Videos

Last Updated: May 17, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Area of Science:

  • Clinical Research
  • Infectious Diseases
  • Pharmacology

Background:

  • Multidrug-resistant tuberculosis (MDR-TB) treatment lacks robust evidence from randomized clinical trials (RCTs).
  • Current MDR-TB treatment relies on expert opinion and case series.
  • There is a critical need for evidence-based treatment strategies for MDR-TB.

Purpose of the Study:

  • To identify and describe challenges in conducting an RCT for MDR-TB treatment.
  • To evaluate the feasibility of a pilot Phase I/II RCT for MDR-TB.
  • To assess the safety and tolerability of linezolid in MDR-TB patients.

Main Methods:

  • A double-blind, placebo-controlled RCT (Tuberculosis Trials Consortium Study 30) was conducted.
  • The study investigated 16 weeks of daily, low-dose linezolid for MDR-TB.
  • Safety and tolerability were primary endpoints.

Main Results:

  • Patient recruitment was significantly lower than targeted (36/64 patients, 56%).
  • Low completion rates were observed, with only 69% of enrolled patients finishing at least 90 doses.
  • A notable discrepancy (25%) was found between assigned treatment and actual study drug administered.

Conclusions:

  • Recruitment and retention of participants in MDR-TB RCTs present substantial challenges.
  • Early patient withdrawal was common, highlighting the need for early supportive interventions.
  • Discrepancies in drug administration underscore the necessity for enhanced administrative controls in clinical trials.